Bonamour Receives CFS Certification from the Personal Care Products Council...
DALLAS Bonamour, Inc., (OTCQB: BONI) announced today that the Company has received its Certificate of Free Sale issued by the Personal Care Products Counsel confirming that Bonamour products comply...
View ArticleRichard Relyea加入昆泰董事会
北卡州研究三角园区 (美国商业资讯)–昆泰(Quintiles)今日宣布已选举Richard Relyea先生担任公司董事。公司的股权投资者3i指定Relyea先生来填补昆泰跨国控股公司(Quintiles Transnational Holdings Inc.)的董事会空缺。选举新的董事是因为Denis Ribon先生即将离开3i公司,同时卸任昆泰董事会董事职务。...
View ArticleAged Care Technology Pioneer, Simavita Releases Prospectus, Sets Date for ASX...
SYDNEY Simavita Limited (TSX VENTURE:SV) has today released the prospectus which will lead the company to its float on the Australian Securities Exchange. Under the offer, which is open from 18...
View ArticlepSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME; Advisory...
WATERTOWN, Mass. pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee...
View ArticleBeiGene Enrolls First Patient in Phase 1 Study of BGB-283
BEIJING BeiGene (Beijing), Co., Ltd., today announced dose administration for the first patient in a Phase 1 study of BGB-283 in patients with B-RAF or K-RAS mutations. BGB-283 is an...
View ArticleBlaze Bioscience Announces Initiation of First-in-Human Phase 1 Clinical...
SEATTLE & MELBOURNE, Australia Blaze Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty Ltd, today announced the initiation of the first Phase 1 clinical study of the first...
View ArticleUnited Health Products Inc. Receives Initial HemoStyp® Order for Australian...
WESTBURY, N.Y. United Health Products, Inc. (OTCQB:UEEC) announced that its Australian distributor, Critical Health Products Ltd., has placed an initial order for HemoStyp® gauze products. The order...
View ArticleOctapharma公司的II/III期复发性多发性硬化症靶向治疗试验入组首例患者
瑞士LACHEN (美国商业资讯)–世界上最大的全球性人类蛋白质制造商之一Octapharma AG今天宣布,该公司的GAM-27 II/III期复发性多发性硬化症(RMS)治疗临床试验已入组最先的2例患者。该研究旨在通过免疫球蛋白(Octagam 5%)静脉给药,在不适用一线药物的患者中寻求较低的年化复发率这一总体临床收益。...
View ArticleTakeda Announces Exclusive License and Option Agreement with Natrogen for...
OSAKA, Japan & DEERFIELD, Ill. & NEW YORK Takeda Pharmaceutical Company Limited (“Takeda”) and Natrogen Therapeutics International, Inc. (“Natrogen”) jointly announced today an agreement...
View ArticleWorld’s First MEVION S250 Proton Therapy Treatment Delivered at Barnes-Jewish...
Smart Multimedia Gallery View of the MEVION S250 Proton Therapy System treatment room at the Siteman Cancer Center at Barnes-Jewish Hospital in St. Louis, MO. (Photo: Business Wire) View and Share...
View ArticleERYTECH Announces the Decision of USPTO to Extend the Additional Exclusivity...
LYON, France Regulatory News: ERYTECH (NYSE Euronext Paris: FR0011471135 – ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology...
View ArticlePeptiDream Announces Collaboration and License Agreement with Lilly to...
TOKYO PeptiDream Inc, a Tokyo-based biopharmaceutical company (PeptiDream)(TOKYO:4587), announced that they have entered into a Collaboration and License Agreement with US-based Eli Lilly and...
View Articleオクタファルマが再発性多発性硬化症の標的治療を検討する第2/3相試験で初の患者組み入れ
スイス・ラッヘン (ビジネスワイヤ) — ヒトタンパク質製品メーカーとして世界最大手のオクタファルマは本日、再発性多発性硬化症(RMS)治療のGAM-27第2/3相臨床試験に患者2人を初めて組み入れたと発表しました。試験では第一選択療法が適さない患者に対し、免疫グロブリン(オクタガム5%)の静脈内投与により、年間再発率の低下という総合的な臨床ベネフィットを支援できるかについて検討します。...
View Articleエリテック、中核プロセス特許の独占期間をほぼ4年延長するというUSPTOの決定を発表
仏リヨン (ビジネスワイヤ) — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的治療薬の開発に当たっているフランスのバイオ製薬企業エリテック(NYSE Euronext Paris: FR0011471135 – ERYP)は、当社の中核プロセスの米国特許が2年からほぼ4年へと独占期間を延長して交付されるという最終許可通知を受領したことを発表します。...
View ArticleCARMAT的生物假体人工心脏首次植入人体
巴黎 (美国商业资讯) –CARMAT (Paris:ALCAR) (FR0010907956, ALCAR)是世界上最先进的全人工心脏课题的设计者和开发者, 为罹患终末期心力衰竭的人士提供另一种医疗选择。该公司宣布,依据ANSM(法国卫生部国家药品及保健产品安全署)和个人保护委员会(伦理委员会)颁发的批复,公司的人工心脏已在一项可行性研究中首次植入人体。...
View Article世界初のMEVION S250による陽子線治療をバーンズ・ジューイッシュ病院で実施
Smart Multimedia Gallery View of the MEVION S250 Proton Therapy System treatment room at the Siteman Cancer Center at Barnes-Jewish Hospital in St. Louis, MO. (Photo: Business Wire) View and Share...
View ArticleMenicon, Azabu University, and Yokohama City University Identify the Glaucoma...
NAGOYA, Japan Menicon announces that an article entitled, “Dogs and humans share a common susceptibility gene SRBD1 for glaucoma risk”, which presents the results of a study conducted by Menicon,...
View Articleカルマトのバイオプロテーゼ人工心臓を初めてヒトに移植
パリ (ビジネスワイヤ) — 世界最先端の完全人工心臓プロジェクトを設計・開発し、末期心不全を患う人々に代替法を提供しているカルマト(Paris:ALCAR)(FR0010907956,...
View ArticleTaro Announces Preliminary Results of Its Self-Tender Offer
HAWTHORNE, N.Y. Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced the preliminary results of its modified “Dutch auction” tender offer to repurchase up to...
View Article